DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20190140

A prospective evaluation of efficacy and safety of topical bromfenac 0.09% over topical flurbiprofen 0.03% after cataract surgery

Sahana K. Hebbar, Deepak P., Nalini G. K., Kavitha C. V., Sahana G. N., Jayashree V. Nagaral

Abstract


Background: Different medications are used to reduce pain and inflammation after cataract surgery. Hence this study was taken up to compare the efficacy and safety of topical bromfenac 0.09% over topical flurbiprofen 0.03% in reducing anterior chamber inflammation and pain after cataract surgery.

Methods: Total of 100 patients who underwent uneventful cataract surgery with posterior chamber intra ocular lens (IOL) implantation were randomly allocated to receive bromfenac 0.09% and flurbiprofen 0.03% topically from first post-operative day onwards for 6 weeks. Assessment of anterior chamber inflammation and pain was done by slit lamp and visual analogue scale respectively on each follow up days. Analysis was done by unpaired t test and Fischer’s exact test.

Results: The response to treatment was earlier in bromfenac group for all the inflammatory changes (significant difference was found on day 7, p<0.05) except for corneal edema where both the groups showed similar response. On 7th day after surgery, 72% patients in flurbiprofen group and 12% in bromfenac group had pain (score1), while on the 14th day none in the bromfenac group complained of pain whereas 4% in flurbiprofen group still had pain. Both the drugs were safe and no clinically serious adverse effects were observed in either of the groups.

Conclusions: This study showed both the medications, topical bromfenac 0.09% and topical flurbiprofen 0.03% effective and safe in reducing pain and anterior chamber inflammation after cataract surgery but the response was earlier with bromfenac 0.09%.


Keywords


Anterior chamber inflammation, Bromfenac, Flurbiprofen, Post-operative pain, Prostaglandins

Full Text:

PDF

References


WHO, Visual impairment and blindness fact sheet, No 282; June 2013. Available at: http://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment/Accessed 16 November 2016

Verma R, Khanna P, Prinja S, Rajput M, Arora V. The national programme for control of blindness in india. Austral Med J. 2011;4(1):1.

Murthy GV, Gupta SK, John N, Vashist P. Current status of cataract blindness and Vision 2020: the right to sight initiative in India. Indian J Ophthalmol. 2008 Nov;56(6):489-94.

Yorston D. Cataract complications. Community Eye Health J. 2005;21(65):1-3.

Dua HS, Attre R. Treatment of post-operative inflammation following cataract surgery - a review. Eur Ophthalmic Rev. 2012;6(2):98-103

Koay P. The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology. The Br J Ophthalmol. 1996 May;80(5):480-5.

Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol (Auckland, NZ). 2009;3:199.

Sweetman CS. Martindale: The Complete Drug Reference. Pharmaceutical Press, London. 35th edn. 2007;52-53.

Perry HD, Donnenfeld ED. Bromfenac ophthalmic solution 0.09%: ocular role and systemic safety profile. Expert Rev Ophthalmol. 2008 Apr 1;3(2):121-9.

Donnenfeld ED, Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin. 2006 Oct 1;46(4):21-40.

Bannale SG, Pundarikaksha HP, Sowbhagya HN. A prospective, open-label study to compare the efficacy and the safety of topical loteprednol etabonate and topical flurbiprofen sodium in patients with post-operative inflammation after cataract extraction. J Clin Diagnostic Res. 2012;6(9):1499-1503.

Schauersberger J, Kruger A, Abela C. Course of postoperative inflammation after implantation of four foldable PCIOL. J Cataract Refract Surg. 1999;125:1116-20.

Cho H, Mozayan A. New look at ocular inflammation control - powerful and fast-acting twice-daily bromfenac for a novel standard in the treatment of inflammation. Eur Ophthalm Review. 2011;5(1):20-6.

Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J. 2008 Jun 1;10(2):229.

Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M, et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. American journal of ophthalmology. 2008 Oct 1;146(4):554-60.

Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, Gow JA, Klier SM, McNamara TR, Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. Curr Med Res Opin. 2011 Sep 1;27(9):1693-703.

Jung JW, Chung BH, Kim EK, Seo KY, Kim TI. The effects of two non-steroidal anti-inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Med J. 2015 Nov 1;56(6):1671-7.

Kawaguchi T, Kida T, Nemoto S, Gekka M, Tanabe T, Miyata K, et al. Effect of bromfenac ophthalmic solution on ocular inflammation and corneal epithelial barrier function following cataract surgery. Folia Ophthalmol Japonica. 2003;54(4):276-9.

Ohara K, Ohkuba A, Miyamoto T. Effect of bromfenac sodium on postoperative inflammation. Jpn J Cataract Refract Surg. 2004;18(2):1-2.

Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR. Bromfenac ophthalmic solution 0.09%(Xibrom) for postoperative ocular pain and inflammation. Ophthalmol. 2007 Sep 1;114(9):1653-62.

Koçak I, Yalvaç IS, Koçak A, Nurözler A, Unlü N, Kasim R, et al. Comparison of the anti-inflammatory effects of diclofenac and flurbiprofen eye drops after cataract extraction. Acta Ophthalmol Scand. 1998 Jun; 76(3):343-5.

Diestelhorst M, Schmidl B, Konen W, Mester U, Raj PS. Efficacy and tolerance of diclofenac sodium 0.1%, flurbiprofen 0.03%, and indomethacin 1.0% in controlling postoperative inflammation. J Cataract Refractive Surg. 1996 Jan 1;22:788-93.